United States Patent 7,056,954: Scope, Claim Strength, and Landscape Impact for 9-cis Retinoic Acid Oral Unit-Dose Compositions
US Patent 7,056,954 claims a narrow formulation concept: an oral unit dosage composition that contains 9-cis retinoic acid (and related pharmaceutically acceptable salts and hydrolysable esters) as the active, plus a pharmaceutically acceptable carrier. Independent claim 1 and the materially identical claim 2 both use the transitional phrase “consisting essentially of”, which sets a constraint on allowable additional ingredients.
What is claimed in US 7,056,954 (claims 1–2)?
Independent claim 1 (paraphrased to structure scope)
A composition in unit dosage form for oral administration, comprising:
- Active ingredient: a compound selected from:
- 9-cis retinoic acid
- pharmaceutically acceptable salts of 9-cis retinoic acid
- pharmaceutically acceptable hydrolysable esters of 9-cis retinoic acid
- Carrier: a pharmaceutically acceptable carrier suitable for oral administration
Independent claim 2
Claim 2 recites essentially the same subject matter as claim 1, with the same limitations:
- oral unit dosage form
- active selected from 9-cis retinoic acid, salts, hydrolysable esters
- pharmaceutically acceptable oral carrier
Key drafting elements that drive scope
- “Unit dosage form”: requires dosing presentation (tablets, capsules, sachets, pellets, or other discrete dosage units).
- “Oral administration”: limits route of delivery to oral.
- “As an active ingredient”: requires the claimed active to be present.
- “Selected from the group consisting of”: closes the active-ingredient options to the listed species (no other actives).
- “Consisting essentially of”: allows additional components only if they do not materially change the basic and novel characteristics. Practically, this restricts the formulation beyond just “any carrier.”
What does “consisting essentially of” mean for formulation design space?
“Consisting essentially of” typically lets the patentee cover compositions that include additional excipients as long as the added matter does not materially affect the claimed characteristics. In a practical freedom-to-operate (FTO) sense for this patent, risk centers on three formulation variables:
1) Whether the product contains the claimed active
If the commercial product’s active is 9-cis retinoic acid, a pharmaceutically acceptable salt, or a hydrolysable ester, the first gate is met.
2) Whether the product is a true unit dosage for oral use
If the product is not packaged or formulated as a unit dose (for example, free-drug bulk formulation intended for compounding, or a non-discrete dosing system), the claim language can be harder to meet.
3) Whether additional excipients change the “basic and novel characteristics”
Because the claims do not specify excipient classes, the “carrier” can be broad. But “consisting essentially of” can still be used to argue that certain formulation approaches materially change the characteristics the claims cover. With no additional limitations stated in the provided claim text, that “basic and novel characteristics” inquiry becomes fact and expert driven, and it tends to be formulation-specific.
How broad are the active-ingredient terms (9-cis retinoic acid family)?
The active group is a closed list:
- 9-cis retinoic acid
- pharmaceutically acceptable salts of 9-cis retinoic acid
- pharmaceutically acceptable hydrolysable esters of 9-cis retinoic acid
Active coverage implications
- Salt forms: include common pharmaceutically acceptable salt strategies (cationic or anionic salt formation), but the claims require salts to be “pharmaceutically acceptable.”
- Hydrolysable esters: this term captures prodrug-like ester derivatives that can convert to 9-cis retinoic acid under physiological conditions (or in vivo/under relevant conditions). That category is usually broad in practice because it can include many ester structures as long as they hydrolyze to the active.
Boundary condition: other retinoids or non-hydrolysable derivatives
Because the “group consisting of” is closed, products using:
- different retinoids (even isomers of retinoic acid beyond those covered)
- non-hydrolysable analogs
- combinations with other actives
should fall outside the literal active-ingredient requirement.
What is the likely infringement trigger for a commercial product?
Literal infringement, based on claim language alone, generally requires:
- Oral administration
- Unit dosage form
- Active ingredient is one of the listed 9-cis retinoic acid family members
- Carrier is pharmaceutically acceptable for oral use
- The formulation is consistent with “consisting essentially of” (i.e., additional components do not materially change claimed characteristics)
The claims do not require:
- a specific dose strength
- a specific excipient composition
- a specific release profile (immediate vs modified)
- a dissolution specification
- manufacturing parameters
That absence makes the claims potentially more difficult to avoid through formulation tweaks, but the “consisting essentially of” language still offers a formulation escape route if additional components are argued to materially alter the basic characteristics.
Where are the practical gaps in the claim set (what is not covered)?
From the provided claim text, US 7,056,954 does not claim any of the following, meaning it is less likely to block competitors who build around different structural or functional formulation choices:
- Specific pharmacokinetic targets
- Specific release technology (enteric coating, sustained release, delayed release)
- Specific ratios of active to carrier
- Specific excipients (e.g., type of binder/disintegrant)
- Specific particle size or polymorphic form
- Specific manufacturing process steps
So the patent is best viewed as an oral unit-dosage formulation claim on the 9-cis retinoic acid family, not as a broad “all oral forms of 9-cis retinoic acid” claim with detailed product constraints.
How does this claim language perform against typical competitors?
A) Direct generic 9-cis retinoic acid oral products
If a competitor markets an oral unit-dosage generic containing:
- 9-cis retinoic acid (or acceptable salt)
- with a standard oral carrier system
the product is structurally close to the claim language.
B) Prodrug/ester versions (hydrolysable esters)
If a competitor markets an oral unit dose of a hydrolysable ester that converts to 9-cis retinoic acid in vivo, the active-ingredient “hydrolysable esters” language can capture it if the ester qualifies as:
- “hydrolysable”
- “pharmaceutically acceptable”
- “of 9-cis retinoic acid”
C) Combination products with additional actives
Because the active ingredient is “selected from the group consisting of” the listed 9-cis retinoic acid species, a combination product can still infringe depending on how strictly “as an active ingredient” and “consisting essentially of” are interpreted. If the claims require the composition to include only the listed active(s), then combinations are a clearer avoidance route. If additional actives are treated as “not materially changing” characteristics under “consisting essentially of,” risk can increase. The claim text you provided does not explicitly forbid additional actives; it only closes the identity of the 9-cis retinoic acid-active family selection.
D) Non-unit dosage formats
Solutions, suspensions, or bulk forms may not meet “unit dosage form” depending on how they are presented and dosed.
What is the likely claim construction focus (litigation levers)?
Given the limited set of limitations, disputes typically narrow to:
- What qualifies as a “hydrolysable ester” of 9-cis retinoic acid
- Whether a salt is “pharmaceutically acceptable”
- What “unit dosage form” means in the context of the accused product
- Whether the accused carrier composition changes the basic and novel characteristics under “consisting essentially of”
- Whether any additional components are permissible under the “consisting essentially of” limitation
The claims are not tied to specific excipient lists, so “consisting essentially of” becomes the main battlefield for formulation differences.
Patent landscape: what can be concluded from the claim structure alone?
With only the provided claim text and without additional bibliographic metadata (publication number, priority dates, specification content, prosecution history), a landscape assessment must be confined to structural effects of this claim set:
Landscape implications
- The patent targets a core formulation category: oral unit doses of the 9-cis retinoic acid family with a pharmaceutically acceptable carrier.
- It is formulation-enabling but not technically specific: because it does not recite release profiles or excipient specifications, it can be difficult for competitors to design around purely by changing carrier chemistry, unless they can argue the formulation materially changes the claimed basic characteristics.
- The “hydrolysable ester” language increases coverage beyond plain 9-cis retinoic acid, which tends to catch prodrug variants and ester pro-moieties that convert to the parent drug.
Practical competitive risk framing
- If a product is an oral unit dosage with active in the 9-cis retinoic acid family, the infringement inquiry is less about whether the excipients are “allowed” and more about whether the formulation satisfies the “consisting essentially of” boundary and whether the prodrug qualifies as “hydrolysable.”
How does the claim set affect R&D decision-making and design-around strategy?
Most protective product differentiation from a literal claim perspective
- Use an active not within the closed list (not 9-cis retinoic acid, not its pharmaceutically acceptable salts, and not its pharmaceutically acceptable hydrolysable esters).
- Avoid “unit dosage form” presentation for oral administration (if product strategy allows).
- If the active is within the list, the remaining lever is the “consisting essentially of” boundary. That usually requires a formulation approach that changes the basic and novel characteristics rather than merely swapping excipients.
Least protective strategy
- Switching from 9-cis retinoic acid to another ester or salt that is still “hydrolysable” and “pharmaceutically acceptable” is unlikely to escape, because those species are expressly included.
Key Takeaways
- US 7,056,954 claims an oral, unit-dose composition whose active ingredient is limited to 9-cis retinoic acid, its pharmaceutically acceptable salts, or its pharmaceutically acceptable hydrolysable esters, plus a pharmaceutically acceptable oral carrier.
- The scope is broadened by the absence of dose strength, excipient specifics, and release-profile limits, while narrowed by “consisting essentially of” and the closed active-ingredient group.
- Prodrug strategies that use hydrolysable esters of 9-cis retinoic acid may sit within the literal active-ingredient scope.
- Design-around is most credible when it avoids the claimed active family, alters the unit-dose requirement, or creates a formulation that can credibly be argued to materially change the claimed characteristics under “consisting essentially of.”
FAQs
1) Does the patent cover only tablets and capsules?
The claims require “unit dosage form” and “oral administration” but do not limit the dosage form type in the provided claim text.
2) Can a salt form be an infringement risk under claim 1?
Yes. Claim 1 expressly includes “pharmaceutically acceptable salts” of 9-cis retinoic acid.
3) Are hydrolysable ester prodrugs covered?
Yes. Claim 1 expressly includes “pharmaceutically acceptable hydrolysable esters” of 9-cis retinoic acid.
4) Does the claim require a specific formulation composition?
No. It requires an oral carrier that is pharmaceutically acceptable, but it does not specify excipient identities or proportions in the provided claim text.
5) What is the most likely point of dispute in litigation?
The likely disputes center on whether the accused formulation fits within “consisting essentially of,” and whether the accused active qualifies as a pharmaceutically acceptable salt or hydrolysable ester.
References
[1] US Patent 7,056,954, claims 1–2 (as provided in prompt).
